Liraglutide is beneficial in reducing weight as wel as increasing forced vital capacity (FVC) in obese patients with COPD. The drug, indicted for treatment of type 2 diabetes mellitus uncontrolled by diet and exercise, also increases carbon monoxide diffusion capacity and improving COPD Assessment Test (CAT) scores in obese patients, suggested a the findings of a new controlled, double-blind trial. The study published in the International Journal of Chronic Obstructive Pulmonary Disease, the researchers wrote that they treated 40 patients with liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for weight loss and for the treatment of type-2 diabetes. The team observed that FVC increased by 7.69 percent (P =.018), and FVC best measure (FVCbest) went up by 0.33 L in the liraglutide group, compared with levels in the placebo group.